At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 204 enrolled
Drug / intervention
5 mg Serlopitant Tablets +1 moredrug
Likely dose
5 mg Serlopitant Tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating 5 mg Serlopitant Tablets and Matching Placebo Tablets for Pruritus and Psoriasis. Completed, enrolled 204 participants across 39 sites.
Detailed Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with plaque psoriasis
Study Details
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionOct 2018
Study CompletionNov 2018
TodayJul 2026
First PostedNov 17, 2017
Enrollment StartNov 1, 2017
Primary CompletionOct 23, 2018
Study CompletionNov 12, 2018
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 8.6 years ago
Interventions
5 mg Serlopitant Tabletsdrug
Serlopitant Tablets
Matching Placebo Tabletsdrug
Placebo Tablets